WO2009138780A3 - Combination of an egfr inhibitor with an endocrine agent and treatment of breast cancer - Google Patents
Combination of an egfr inhibitor with an endocrine agent and treatment of breast cancer Download PDFInfo
- Publication number
- WO2009138780A3 WO2009138780A3 PCT/GB2009/050495 GB2009050495W WO2009138780A3 WO 2009138780 A3 WO2009138780 A3 WO 2009138780A3 GB 2009050495 W GB2009050495 W GB 2009050495W WO 2009138780 A3 WO2009138780 A3 WO 2009138780A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- breast cancer
- combination
- egfr inhibitor
- endocrine agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A method of treating hormone sensitive breast cancer, in a warm-blooded animal, such as man, that has not received prior endocrine therapy, in need of such treatment which comprises administering to said animal an effective amount of an EGFR inhibitor in combination with an effective amount of an endocrine agent suitable for use in the treatment of breast cancer. Also described are combinations and uses thereof in the method according to the invention.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5272108P | 2008-05-13 | 2008-05-13 | |
US61/052,721 | 2008-05-13 | ||
US12058608P | 2008-12-08 | 2008-12-08 | |
US61/120,586 | 2008-12-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009138780A2 WO2009138780A2 (en) | 2009-11-19 |
WO2009138780A3 true WO2009138780A3 (en) | 2010-03-04 |
Family
ID=40942791
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2009/050495 WO2009138780A2 (en) | 2008-05-13 | 2009-05-11 | Therapeutic treatment - 355 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009138780A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019211322A1 (en) * | 2018-05-02 | 2019-11-07 | Mithra Pharmaceuticals S.A. | Treatment of advanced estrogen receptor positive breast cancer |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002005791A2 (en) * | 2000-07-18 | 2002-01-24 | Pharmacia Italia Spa | Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor |
WO2005028469A1 (en) * | 2003-09-19 | 2005-03-31 | Astrazeneca Ab | Quinazoline derivatives |
WO2007054551A1 (en) * | 2005-11-11 | 2007-05-18 | Boehringer Ingelheim International Gmbh | Combination treatment of cancer comprising egfr/her2 inhibitors |
-
2009
- 2009-05-11 WO PCT/GB2009/050495 patent/WO2009138780A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002005791A2 (en) * | 2000-07-18 | 2002-01-24 | Pharmacia Italia Spa | Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor |
WO2005028469A1 (en) * | 2003-09-19 | 2005-03-31 | Astrazeneca Ab | Quinazoline derivatives |
WO2007054551A1 (en) * | 2005-11-11 | 2007-05-18 | Boehringer Ingelheim International Gmbh | Combination treatment of cancer comprising egfr/her2 inhibitors |
Non-Patent Citations (3)
Also Published As
Publication number | Publication date |
---|---|
WO2009138780A2 (en) | 2009-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009064444A9 (en) | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents | |
TN2010000208A1 (en) | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents | |
WO2008137867A3 (en) | Compositions comprising mir34 therapeutic agents for treating cancer | |
EP4316517A3 (en) | Combination therapy against cancer | |
EA201300171A1 (en) | METHODS AND COMPOSITIONS FOR LIVER CANCER THERAPY | |
MY166014A (en) | Combination therapy methods for treating proliferative diseases | |
WO2011037643A3 (en) | Compositions and methods for detecting and treating prostate carcinoma | |
WO2012018404A3 (en) | Use of her3 binding agents in prostate treatment | |
WO2008077077A3 (en) | Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors | |
MX2022009759A (en) | Diarylhydantoin compounds. | |
WO2006102504A3 (en) | Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors | |
EP3581182A4 (en) | Combination treating prostate cancer, pharmaceutical composition and treatment method | |
PH12015500246A1 (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor | |
WO2011130164A3 (en) | Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer | |
WO2010017443A3 (en) | Anti-beta-2-microglobulin agents and the use thereof | |
WO2008060945A3 (en) | Diagnosis and treatment of breast cancer | |
WO2009108857A3 (en) | Combination therapy for prostate cancer | |
WO2009016488A3 (en) | Compositions comprising tetracyclic antidepressants for treatment of cancer and related methods | |
WO2008134752A3 (en) | Methods and compositions for the treatment of cancer | |
WO2008052054A3 (en) | Synergism between activated immune cells and conventional cancer therapies | |
WO2012170742A3 (en) | Treatment and prevention of cancer with hmgb1 antagonists | |
WO2011056566A3 (en) | Compounds and methods for treatment of cancer | |
WO2013066485A3 (en) | Compositions and methods for treatment of metastatic cancer | |
WO2011153243A3 (en) | Anti-angiogenesis therapy for treating gastric cancer | |
WO2008115478A3 (en) | Method of cancer detection and treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09746097 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09746097 Country of ref document: EP Kind code of ref document: A2 |